Total Payments
$29,525
2024 Payments
$331.69
Companies
52
Transactions
245
Medicare Patients
4,289
Medicare Billing
$417,331
Payment Breakdown by Category
Research$18,661 (63.2%)
Food & Beverage$4,464 (15.1%)
Consulting$4,270 (14.5%)
Travel$1,358 (4.6%)
Education$772.01 (2.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $18,661 | 4 | 63.2% |
| Food and Beverage | $4,464 | 213 | 15.1% |
| Consulting Fee | $4,270 | 1 | 14.5% |
| Travel and Lodging | $1,358 | 5 | 4.6% |
| Education | $772.01 | 22 | 2.6% |
Payments by Type
Research
$18,661
4 transactions
General
$10,864
241 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $18,661 | 4 | $0 (2021) |
| Gilead Sciences, Inc. | $6,145 | 17 | $0 (2023) |
| Medtronic Vascular, Inc. | $612.09 | 2 | $0 (2017) |
| Genentech USA, Inc. | $393.33 | 28 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $353.59 | 20 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $345.74 | 20 | $0 (2023) |
| PFIZER INC. | $344.93 | 27 | $0 (2024) |
| Amgen Inc. | $261.74 | 15 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $221.75 | 15 | $0 (2019) |
| Janssen Products, LP | $198.95 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $331.69 | 15 | AstraZeneca Pharmaceuticals LP ($64.36) |
| 2023 | $6,204 | 20 | Gilead Sciences, Inc. ($6,097) |
| 2022 | $383.79 | 8 | E.R. Squibb & Sons, L.L.C. ($100.09) |
| 2021 | $440.52 | 14 | Pharmacyclics LLC, An AbbVie Company ($159.99) |
| 2020 | $336.22 | 16 | SANOFI-AVENTIS U.S. LLC ($99.95) |
| 2019 | $1,966 | 52 | Eli Lilly and Company ($1,206) |
| 2018 | $18,238 | 55 | Eli Lilly and Company ($17,384) |
| 2017 | $1,625 | 65 | Medtronic Vascular, Inc. ($612.09) |
All Payment Transactions
245 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/01/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $22.07 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Genentech USA, Inc. | Lunsumio (Biological), Polivy | Food and Beverage | In-kind items and services | $23.29 | General |
| Category: BioOncology | ||||||
| 10/08/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $24.60 | General |
| Category: Oncology | ||||||
| 09/17/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $23.37 | General |
| Category: Oncology | ||||||
| 08/27/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: Oncology | ||||||
| 08/27/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $21.66 | General |
| 08/26/2024 | Amgen Inc. | IMDELLTRA (AMG 757) (Biological) | Food and Beverage | In-kind items and services | $32.83 | General |
| Category: Hematology | ||||||
| 08/06/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $27.92 | General |
| Category: ONCOLOGY | ||||||
| 07/30/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $29.52 | General |
| Category: Oncology | ||||||
| 05/21/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.09 | General |
| Category: Oncology | ||||||
| 05/15/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: Oncology | ||||||
| 04/30/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: ONCOLOGY | ||||||
| 04/09/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2023 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $23.95 | General |
| Category: Oncology | ||||||
| 10/11/2023 | PFIZER INC. | ORGOVYX (Drug) | Education | In-kind items and services | $21.00 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2023 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $13.86 | General |
| Category: ONCOLOGY | ||||||
| 09/01/2023 | PFIZER INC. | ORGOVYX (Drug) | Education | In-kind items and services | $21.00 | General |
| Category: ONCOLOGY | ||||||
| 09/01/2023 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $13.86 | General |
| Category: ONCOLOGY | ||||||
| 05/26/2023 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $13.86 | General |
| Category: ONCOLOGY | ||||||
| 05/03/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $4,270.00 | General |
| Category: ONC | ||||||
| 05/03/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $45.02 | General |
| Category: ONC | ||||||
| 05/03/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $18.00 | General |
| Category: ONC | ||||||
| 04/22/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: ONC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 3 STUDY OF NONSTEROIDAL AROMATASE INHIBITORS -ANASTROZOLE OR LETROZOLE- PLUS LY2835219 A CDK4-6 INHIBITOR OR PLACEBO IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2-NEGATIVE LOCOREGIONALLY RECURRENT | Eli Lilly and Company | $18,623 | 3 |
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $38.20 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 907 | 1,528 | $259,094 | $99,634 |
| 2022 | 10 | 1,057 | 1,572 | $268,813 | $100,346 |
| 2021 | 9 | 1,185 | 1,840 | $305,907 | $119,888 |
| 2020 | 9 | 1,140 | 1,804 | $289,151 | $97,463 |
Total Patients
4,289
Total Services
6,744
Medicare Billing
$417,331
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 346 | 763 | $131,241 | $49,998 | 38.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 263 | 326 | $36,214 | $12,881 | 35.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 57 | 164 | $18,860 | $9,811 | 52.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 61 | 61 | $22,021 | $7,743 | 35.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 59 | 69 | $17,250 | $6,928 | 40.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 54 | 62 | $10,168 | $5,649 | 55.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 23 | 23 | $6,555 | $2,067 | 31.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 13 | $7,800 | $1,727 | 22.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 17 | 17 | $6,885 | $1,692 | 24.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 14 | 30 | $2,100 | $1,138 | 54.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 393 | 772 | $132,784 | $49,270 | 37.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 344 | 407 | $45,177 | $16,996 | 37.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 77 | 77 | $27,797 | $10,561 | 38.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 60 | 63 | $15,750 | $6,456 | 41.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 57 | 110 | $12,650 | $5,757 | 45.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 43 | 43 | $12,255 | $3,997 | 32.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 35 | $5,740 | $2,735 | 47.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $8,400 | $2,050 | 24.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 14 | 14 | $5,670 | $1,433 | 25.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 21 | 37 | $2,590 | $1,091 | 42.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 439 | 883 | $151,876 | $59,680 | 39.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 393 | 503 | $55,833 | $22,040 | 39.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 78 | 78 | $28,158 | $10,043 | 35.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 70 | 74 | $18,500 | $7,915 | 42.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 59 | 131 | $15,065 | $7,176 | 47.6% |
About Dr. Ibrahim Shalaby, MD
Dr. Ibrahim Shalaby, MD is a Medical Oncology healthcare provider based in Lubbock, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053374769.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ibrahim Shalaby, MD has received a total of $29,525 in payments from pharmaceutical and medical device companies, with $331.69 received in 2024. These payments were reported across 245 transactions from 52 companies. The most common payment nature is "" ($18,661).
As a Medicare-enrolled provider, Shalaby has provided services to 4,289 Medicare beneficiaries, totaling 6,744 services with total Medicare billing of $417,331. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Lubbock, TX
- Active Since 04/11/2006
- Last Updated 07/20/2009
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1053374769
Products in Payments
- Trodelvy (Drug) $6,097
- TurboHawk (Device) $612.09
- IMBRUVICA (Drug) $221.38
- ZYTIGA (Drug) $198.95
- KEYTRUDA (Biological) $195.74
- NERLYNX (Drug) $175.19
- GAZYVA (Biological) $155.42
- JEVTANA (Drug) $131.62
- OPDIVO (Biological) $129.72
- ADCETRIS (Biological) $121.63
- TAZVERIK (Drug) $99.99
- FASLODEX (Drug) $98.01
- NINLARO (Drug) $97.52
- XTANDI (Drug) $95.24
- Kyprolis (Biological) $88.17
- Avastin (Biological) $84.99
- SUTENT (Drug) $65.85
- IMFINZI (Drug) $64.77
- XALKORI (Drug) $60.92
- Neulasta (Biological) $57.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.